SYN-005 Related News | SYN Message Board Posts

Synthetic Biologics Inc.

  SYN website

SYN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4735 of 4776  at  3/15/2019 2:34:15 PM  by


The following message was updated on 3/15/2019 2:35:27 PM.

 In response to msg 4734 by  recon1221.1221
view thread

Re: SYN-005 Related News

I don't think so. It's still listed in the product pipeline on the website, and, in the 02/27/2019 Annual Report (page 16) SYN states the research agreement has been extended to 2021, plus they reference their patents and patent applications:
In connection with the Texas License Agreement, we also entered into a Sponsored Research Agreement (the “Sponsored Research Agreement”) with the University pursuant to which the University will perform certain research work related to pertussis under the direction of Dr. Jennifer Maynard. All inventions conceived during such research shall be subject to the Texas License Agreement and we will obtain certain rights to patents and technology developed during the course of such research. We paid the University a fixed fee for the first year of $303,287 and the second and third years of $316,438 and $328,758, respectively. The Sponsored Research Agreement was amended on October 22, 2015, to extend its termination date to January 15, 2017, on September 2, 2016 to extend the agreement until January 15, 2018; on August 22, 2017 to extend the agreement until January 17, 2019; and again on August 24, 2018 to extend the agreement until January 21, 2021; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Sponsored Research Agreement which remain uncured for 60 days after receipt of notice, automatically upon our bankruptcy or insolvency and by us in our sole discretion at any time after the one year anniversary of the date of execution thereof upon no less than 90 days’ notice. Upon a termination after December 31, 2014 or due to a breach by the University, we shall only be responsible for all reasonable expenses that do not exceed the fixed annual amount and that are incurred by the University prior to the termination date for services performed prior to the termination date
We have an issued U.S. patent and patents pending in the U.S. and internationally (e.g. Europe, China, Japan, Australia, and China) on compositions and uses of SYN-005 that are co-owned by UT and ourselves or licensed to us, and we have an issued U.S. patent and patent applications on other pertussis mAbs licensed from UT.
005 currently is a minor direct expense to SYN ($6K for 2018 per table on page 55 of the Annual Report, down from $79K in 2017).

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 352
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Financial Market Data provided by